Breast cancer prevention in the era of precision medicine

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Narod, Steven A ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; EDITORIAL; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; HUMAN; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST NEOPLASMS; CANADA; EARLY DIAGNOSIS; EPIDEMIOLOGY; FEMALE; GENETICS; INSURANCE; MORTALITY; PERSONALIZED MEDICINE; PROCEDURES; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED KINGDOM; UNITED STATES;

ANTICARCINOGENIC AGENTS; BRCA2 PROTEIN; BREAST NEOPLASMS; CANADA; EARLY DETECTION OF CANCER; FEMALE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GREAT BRITAIN; HUMANS; INDIVIDUALIZED MEDICINE; INSURANCE COVERAGE; MASTECTOMY, MODIFIED RADICAL; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE; TAMOXIFEN; UNITED STATES;

EID: 84928759481     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv078     Document Type: Editorial

References (12)

1. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31(1):33-36.
2. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087-1093.
3. Mavaddat N, Pharoah PD, Michailidou K, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst (2015); 107(5):djv036 doi:10. 1093/jnci/djv036.
4. Cancer Incidence in Five Continents, IARC Scientific publications, Lyon, 2002.
5. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
6. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med. 2014;370(21):1965-1967.
7. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107(1):24-30.
8. Phi XA, Houssami N, Obdeijn IM, Warner E, et al. Magnetic Resonance Imaging Improves Breast Screening Sensitivity in BRCA Mutation Carriers Age 50 Years: Evidence From an Individual Patient Data Meta-Analysis. J Clin Oncol. 2015;33(4):349-356.
9. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67-75.
10. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA. 2014;312(9):902-914.
11. Metcalfe KA, Narod SA. Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst. 2002;94(20):1564-1569.
12. Collins FS, Varmus H. A New Initiative on Precision Medicine. N Engl J Med. 2015; In press.